Kronos Bio Statistics
Total Valuation
Kronos Bio has a market cap or net worth of $61.30 million. The enterprise value is -$65.24 million.
| Market Cap | 61.30M |
| Enterprise Value | -65.24M |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Kronos Bio has 60.09 million shares outstanding. The number of shares has increased by 4.15% in one year.
| Shares Outstanding | 60.09M |
| Shares Change (YoY) | +4.15% |
| Shares Change (QoQ) | +2.14% |
| Owned by Insiders (%) | 19.59% |
| Owned by Institutions (%) | 45.16% |
| Float | 43.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.08 |
| Forward PS | 8.23 |
| PB Ratio | 0.45 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.32, with a Debt / Equity ratio of 0.20.
| Current Ratio | 8.32 |
| Quick Ratio | n/a |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.70% and return on invested capital (ROIC) is -76.22%.
| Return on Equity (ROE) | -68.70% |
| Return on Assets (ROA) | -52.00% |
| Return on Capital (ROIC) | -76.22% |
| Revenue Per Employee | $122,371 |
| Profits Per Employee | -$1.88M |
| Employee Count | 62 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.96% in the last 52 weeks. The beta is 1.85, so Kronos Bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.85 |
| 52-Week Price Change | -43.96% |
| 50-Day Moving Average | 1.11 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 45.89 |
| Average Volume (30 Days) | 432,883 |
Short Selling Information
The latest short interest is 686,836, so 1.14% of the outstanding shares have been sold short.
| Short Interest | 686,836 |
| Short Previous Month | 662,733 |
| Short % of Shares Out | 1.14% |
| Short % of Float | 1.57% |
| Short Ratio (days to cover) | 1.47 |
Income Statement
In the last 12 months, Kronos Bio had revenue of $7.59 million and -$116.39 million in losses. Loss per share was -$1.99.
| Revenue | 7.59M |
| Gross Profit | 7.59M |
| Operating Income | -125.33M |
| Pretax Income | -116.39M |
| Net Income | -116.39M |
| EBITDA | -111.36M |
| EBIT | -116.39M |
| Loss Per Share | -$1.99 |
Balance Sheet
The company has $154.01 million in cash and $27.47 million in debt, giving a net cash position of $126.54 million or $2.11 per share.
| Cash & Cash Equivalents | 154.01M |
| Total Debt | 27.47M |
| Net Cash | 126.54M |
| Net Cash Per Share | $2.11 |
| Equity / Book Value | 136.97M |
| Book Value Per Share | 2.28 |
| Working Capital | 139.33M |
Cash Flow
In the last 12 months, operating cash flow was -$96.53 million and capital expenditures -$560,000, giving a free cash flow of -$97.09 million.
| Operating Cash Flow | -96.53M |
| Capital Expenditures | -560,000 |
| Free Cash Flow | -97.09M |
| FCF Per Share | -$1.63 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,651.92% and -1,534.11%.
| Gross Margin | 100.00% |
| Operating Margin | -1,651.92% |
| Pretax Margin | -1,534.11% |
| Profit Margin | -1,534.11% |
| EBITDA Margin | -1,467.76% |
| EBIT Margin | -1,534.11% |
| FCF Margin | -1,279.74% |
Dividends & Yields
Kronos Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.15% |
| Shareholder Yield | -4.15% |
| Earnings Yield | -189.89% |
| FCF Yield | -158.40% |
Analyst Forecast
The average price target for Kronos Bio is $4.13, which is 304.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.13 |
| Price Target Difference | 304.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 112.16% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kronos Bio has an Altman Z-Score of -4.47 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.47 |
| Piotroski F-Score | 3 |